AN2 Therapeutics, Inc.

NASDAQ: ANTX · Healthcare · Biotechnology

PublicHQ Menlo Park, CA · San MateoCIK 0001880438Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 57DQ —GM —SS 40

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$35.2M

Employees

as of 2026-08-14

Market cap

$215.4M

as of 2026-08-14

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$35.2M-$35.2M2025

Operating income-$38.1M-$38.1M2025

Total assets$62.0M$62.0M2025

Liabilities$8.9M$8.9M2025

Equity$53.1M$53.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is AN2 Therapeutics, Inc.’s financial profile?

AN2 Therapeutics, Inc. earned -$35.2M in FY2025 net income.

Peers · Healthcare

Aurora Cannabis Inc.——Greenwich LifeSciences, Inc.——Immunic, Inc.——Galectin Therapeutics Inc.——PepGen Inc.——Cardiol Therapeutics Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$053D

Key facts

CEOEric E. Easom

SectorHealthcare

IndustryBiotechnology

HeadquartersMenlo Park, CA

ExchangeNASDAQ: ANTX

Employees21

IPO date2022-03-25

Latest filings

10-Q2026-08-11 8-K2026-08-11 8-K2026-06-09 8-K2026-06-04 8-K2026-05-11 10-Q2026-05-11 DEF 14A2026-04-22 8-K2026-04-09

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.